Literature DB >> 29475770

Declining prevalence and increasing awareness of HCV infection in Italy: A population-based survey in five metropolitan areas.

Angelo Andriulli1, Tommaso Stroffolini2, Andrea Mariano3, Maria Rosa Valvano4, Ignazio Grattagliano5, Antonio Massimo Ippolito4, Adriano Grossi6, Giuseppina Brancaccio6, Christian Coco7, Maurizio Russello7, Antonina Smedile8, Elisa Petrini8, Silvia Martini8, Giovanni Battista Gaeta6, Mario Rizzetto8.   

Abstract

BACKGROUND: Data on the prevalence of hepatitis C virus (HCV) infection in Italy are outdated and usually derived from studying residents in small towns.
METHODS: To assess prevalence of and risk factors for HCV infection among Italian residents in 5 metropolitan areas, subjects ≥20 years of age were randomly selected from the list of the general practitioners' registers in 2015. Anti-HCV was tested by a salivary test; HCV-RNA, HCV genotypes, and ALT were determined in positive individuals. Logistic regression analysis evaluated independent risk factors for HCV.
RESULTS: Of the 4907 enrolled subjects, 112 (2.3%) tested anti-HCV positive. The prevalence of HCV increased with age, from 0.2% in subjects born after the year 1984, to 4.2% in those born before the year 1935 (P < 0.01). The birth-cohort prevalence peaked (7.0%) in elderly. Serum HCV-RNA was detected in 1.7% of the whole population. Nearly 80% of anti-HCV subjects were aware of their status. Age > 70 years, low education level, past use of glass syringes, blood transfusion, intravenous drug use, and cohabitation with an anti-HCV positive subject predicted the HCV positivity.
INTERPRETATION: In metropolitan areas in Italy, HCV is prevalent in elderly, reflecting a cohort effect determined by modalities of viral transmission no longer operative. The impact of the infection will further diminish in the years to come due to the natural depletion of the reservoir of the virus. This age pattern and the high proportion of subjects aware of their status do not warrant a policy of screening.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Epidemiology; HCV; HCV infection; Risk factors

Mesh:

Substances:

Year:  2018        PMID: 29475770     DOI: 10.1016/j.ejim.2018.02.015

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  22 in total

1.  Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data.

Authors:  Andrea Marcellusi; Raffaella Viti; Loreta A Kondili; Stefano Rosato; Stefano Vella; Francesco Saverio Mennini
Journal:  Pharmacoeconomics       Date:  2019-02       Impact factor: 4.981

2.  High prevalence of unawareness of HCV infection status among both HCV-seronegative and seropositive people living with human immunodeficiency virus in Taiwan.

Authors:  Chun-Yuan Lee; Pei-Hua Wu; Meng-Wei Lu; Tun-Chieh Chen; Po-Liang Lu
Journal:  PLoS One       Date:  2021-05-06       Impact factor: 3.240

3.  Hepatitis C screening during SARS-CoV-2 testing or vaccination. Experience in an area of southern Italy in the province of Salerno.

Authors:  Pietro Torre; Monica Annunziata; Roberta Sciorio; Carmine Coppola; Mario Masarone; Marcello Persico
Journal:  Liver Int       Date:  2022-04-23       Impact factor: 8.754

4.  Prevalence of hepatitis C in the adult population of Bulgaria: a pilot study.

Authors:  Ida Sperle; Stine Nielsen; Martyna Gassowski; Zlatina Naneva; Tanya Perchemlieva; Andrew Amato-Gauci; Matthias An der Heiden; Viviane Bremer; Elitsa Golkocheva-Markova; Kristiyan Hristov; Elena Kaneva; Yanita Simeonova; Tencho Tenev; Tonka Varleva; Erika Duffell; Ruth Zimmermann
Journal:  BMC Res Notes       Date:  2020-07-07

5.  Optimization of hepatitis C virus screening strategies by birth cohort in Italy.

Authors:  Loreta A Kondili; Ivane Gamkrelidze; Sarah Blach; Andrea Marcellusi; Massimo Galli; Salvatore Petta; Massimo Puoti; Stefano Vella; Homie Razavi; Antonio Craxi; Francesco S Mennini
Journal:  Liver Int       Date:  2020-04-02       Impact factor: 5.828

6.  Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia.

Authors:  Masoud Behzadifar; Hasan Abolghasem Gorji; Aziz Rezapour; Nicola Luigi Bragazzi
Journal:  J Virus Erad       Date:  2019-04-01

7.  Developing and Piloting a Standardized European Protocol for Hepatitis C Prevalence Surveys in the General Population (2016-2019).

Authors:  Ida Sperle; Stine Nielsen; Viviane Bremer; Martyna Gassowski; Henrikki Brummer-Korvenkontio; Roberto Bruni; Anna Rita Ciccaglione; Elena Kaneva; Kirsi Liitsola; Zlatina Naneva; Tanya Perchemlieva; Enea Spada; Salla E Toikkanen; Andrew J Amato-Gauci; Erika Duffell; Ruth Zimmermann
Journal:  Front Public Health       Date:  2021-05-28

8.  High Rates of Hidden HCV Infections among Hospitalized Patients Aged 55-85.

Authors:  Annarita Valeria Piazzolla; Giulia Paroni; Francesca Bazzocchi; Mauro Cassese; Antonio Cisternino; Luigi Ciuffreda; Franco Gorgoglione; Leonardo Gorgoglione; Vincenzo Palazzo; Natale Sciannamè; Marco Taurchini; Pasquale Vaira; Giovanna Cocomazzi; Maria Maddalena Squillante; Filippo Aucella; Nicola Cascavilla; Salvatore De Cosmo; Michelantonio Fania; Antonio Greco; Antonio Laborante; Maurizio Leone; Evaristo Maiello; Mauro Salvatori; Lazzaro Di Mauro; Alessandra Mangia
Journal:  Pathogens       Date:  2021-06-03

9.  Forecasting Hepatitis C liver disease burden on real-life data. Does the hidden iceberg matter to reach the elimination goals?

Authors:  Loreta A Kondili; Sarah Robbins; Sarah Blach; Ivane Gamkrelidze; Anna L Zignego; Maurizia R Brunetto; Giovanni Raimondo; Gloria Taliani; Andrea Iannone; Francesco P Russo; Teresa A Santantonio; Massimo Zuin; Luchino Chessa; Pierluigi Blanc; Massimo Puoti; Maria Vinci; Elke M Erne; Mario Strazzabosco; Marco Massari; Pietro Lampertico; Maria G Rumi; Alessandro Federico; Alessandra Orlandini; Alessia Ciancio; Guglielmo Borgia; Pietro Andreone; Nicola Caporaso; Marcello Persico; Donatella Ieluzzi; Salvatore Madonia; Andrea Gori; Antonio Gasbarrini; Carmine Coppola; Giuseppina Brancaccio; Angelo Andriulli; Maria G Quaranta; Simona Montilla; Homie Razavi; Mario Melazzini; Stefano Vella; Antonio Craxì
Journal:  Liver Int       Date:  2018-08-10       Impact factor: 5.828

10.  Sofosbuvir-based therapies in genotype 2 hepatitis C virus cirrhosis: A real-life experience with focus on ribavirin dose.

Authors:  Carlo Smirne; Antonio D'Avolio; Mattia Bellan; Alessandro Gualerzi; Maria G Crobu; Mario Pirisi
Journal:  Pharmacol Res Perspect       Date:  2021-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.